Evidence-based treatment of Gastrointestinal Stromal Tumor (GIST) with tyrosine kinase inhibitors - Imatinib and sunitinib

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 5, 2011, Pages 733-737

  Nishida, Toshirou ^a   Omori, Takeshi ^a   Ueshima, Shigeyuki ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

Author keywords

Imatinib; KIT gene; PDGFRA gene; Sunitinib

Indexed keywords

IMATINIB; SUNITINIB;

ARTICLE; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79961009234     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chi P, Chen Y, Zhang L, et al: ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467: 849-853, 2010.
2. Nishida T, Takahashi T and Miyazaki Y: Gastrointestinal stromal tumor: a bridge between bench and bedside. Gastric Cancer 12: 175-188, 2010.
3. Yoo C, Ryu MH, Kang BW, et al: Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 28: 1554-1559, 2010.
4. Blanke CD, Demetri GD, von Mehren M, et al: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26: 620-625, 2008. (Pubitemid 351264357)
5. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26: 626-632, 2008. (Pubitemid 351264358)
6. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127-1134, 2004. (Pubitemid 39296599)
7. Nishida T, Shirao K, Sawaki A, et al: Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 13: 244-251, 2008. (Pubitemid 351871892)
8. Le Cesne A, Ray-Coquard I, Bui BN, et al: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 11: 942-949, 2010.
9. Le Cesne A, Van Glabbeke M, Verweij J, et al: Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 27: 3969-3974, 2009.
10. Demetri GD, Wang Y, Wehrle E, et al: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 27: 3141-3147, 2009.
11. Demetri GD, von Mehren M, Antonescu CR, et al: NCCN Task Force report update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 8(suppl 2): S1-41; quiz S42-4, 2010.
12. Casali PG, Jost L, Reichardt P, ESMO Guidelines Working Group: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(suppl 4): 64-67, 2009.
13. Nishida T, Hirota S, Yanagisawa A, et al: Clinical practice guideline for gastrointestinal stromal tumor (GIST) in Japan. Int J Clin Oncol 13: 416-430, 2008.
14. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST): Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1, 640 patients. J Clin Oncol 28: 1247-1253, 2010.
15. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour a randomised, double-blind, placebo-controlled trial. Lancet 373: 1097-1104, 2009.
16. Chow LQ and Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884-896, 2007. (Pubitemid 350002890)
17. Heinrich MC, Maki RG, Corless CL, et al: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26: 5352-5359, 2008.
18. Nishida T, Takahashi T, Nishitani A, et al: Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 14: 143-149, 2009.
19. George S, Blay JY, Casali PG, et al: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45: 1959-1968, 2009.
20. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329-1338, 2006. (Pubitemid 44528723)